BAY1143269 / Bayer - LARVOL DELTA

Preclinical anti-angiogenic and anti-cancer activities of BAY1143269 in glioblastoma via targeting oncogenic protein expression. (PubMed, Pharmacol Res Perspect) - "Immunoblotting analysis demonstrated significantly less phosphorylated-eIF4E (p-eIF4E), cluster of differentiation 31 (CD31) (microvascular endothelial cell marker), and VEGF in tumors from drug-treated mice. In summary, the inhibition of glioblastoma angiogenesis with BAY1143269 may provide an alternative approach for anti-glioblastoma therapy."

Journal • Preclinical • Brain Cancer • Glioblastoma • Oncology • Solid Tumor • CD31 • CDK7 • EIF4E • PECAM1

Progress in developing MNK inhibitors. (PubMed, Eur J Med Chem) - "Currently, three inhibitors (BAY1143269, eFT508 and ETC-206) are in various stages of clinical trials for the treatment of solid cancers or leukemia, either alone or combined with inhibitors of other protein kinase. In this review, we summarize the diverse MNK inhibitors that have been reported in patents and other literature, including those with activities in vitro and/or in vivo."

Journal • Review • Hematological Malignancies • Leukemia • Metabolic Disorders • Oncology • Solid Tumor • EIF4E